Skip to Main Content

The field of organs-on-chips scored an early victory Tuesday: Boston organ-on-a-chip startup Emulate has partnered with the Food and Drug Administration to test whether the technology works for toxicity screening purposes.

But this is just an early gambit into the wider world of organs-on-chips — since tox screening accounts for just 10 percent of the preclinical testing typically conducted on animals, said Dr. Thomas Hartung, who is director of the Center for Alternatives to Animal Testing at Johns Hopkins University.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.